Korean Journal of Food Science and Technology (한국식품과학회지)

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지

Effects of Anti-Helicobacter pylori IgY Powder to Protect Mice from Helicobacter pylori

Helicobacter pylori 감염생쥐에서 항-Helicobacter pylori 난황항체 분말의 효과

  • Published : 2006.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Effects of anti-Helicobacter pylori IgY powder on H. pylori infection were evaluated 3 and 7 weeks after powder feeding by urease, PCR, and histological tests, and specific IgG assay of murine gastric tissue using mouse model. To produce anti-H. pylori IgY powder, laying hens were immunized with H. pylori prior to egg yolk harvest. C57BL/6 mice showing high response to H. pylori were infected with H. pylori and fed with the anti-H. pylori IgY powder. In urease and PCR tests, urease activity and gene count of anti-H. pylori IgY powder-fed group significantly decreased in comparison with control. Histological results indicated anti-H. pylori IgY powder effectively protected mice from H. pylori.

본 연구는 H. pylori를 산란계에 면역화하여 얻은 항-H. pylori 난황항체 분말의 H. pylori에 대한 억제효과를 알아보기 위하여 실시하였다. 마우스의 종에 따라서 H. pylori에 대한 감수성의 차이가 있다고 보고된 바 있다(25). Richard 등의 연구결과에 의하면 C57BL/6 mice는 H. pylori에 대하여 약 70%의 감수성을 가진 것으로 보고하였다(26). 이번 실험에서는 7주째의 urease test 결과 항-H. pylori 난황항체 분말을 급이한 군에서 33%의 낮은 양성율을 보였고, 흡광도 측정결과도 유의적으로 감소하였다. 조직학적 검사에서 접종대조군의 위조직은 염증성 세포의 집적 등 특이적인 염증성 변화를 동반하였지만, 항-H. pylori 난황항체 분말을 급이한 군에서는 특이적 변화를 관찰할 수 없었다. H. pylori의 제균효과를 확인하는 방법중 하나인 ureA 유전자 확인결과, 항-H. pylori 난황항체 분말을 급이한 군에서는 3주째보다 7주째 많이 감소하였다. 항-H. pylori 난황항체 분말의 급이시기는 감염전이나 감염후에 큰 차이를 보이지 않았으며, 급이수준은 5%보다는 10% 첨가수준이 약간 높게 나타났다. 이 연구결과로 동물시험에서 항-H. pylori 난황항체 분말이 H. pylori 억제 효과가 있음이 확인되었다.

Keywords

References

  1. Owen RJ. Helicobacter-species classification and identification. Br. Med. Bull. 54: 17-30 (1998) https://doi.org/10.1093/oxfordjournals.bmb.a011667
  2. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1: 1273-1275 (1983)
  3. Hunt RH. Eradication of Helicobacter pylori infection. Am. J. Med. 100(5A): 42S-50S (1996) https://doi.org/10.1016/S0002-9343(96)80228-2
  4. Rhee KH, Yoon HS. Prevalence of Helicobacter pylori infection in korea. J. Korean. Soc. Microbiol. 25: 475-490. (1990)
  5. NIH (National Institute of Health) Consensus Conference. Helicobacter pylori in peptic ulcer disease. J. Am. Med. Assoc. 272: 65-69 (1994) https://doi.org/10.1001/jama.272.1.65
  6. Peterson WI.. Helicobacter pylori and peptic ulcer disease. New England J. Med. 324: 1043-1048 (1991) https://doi.org/10.1056/NEJM199104113241507
  7. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicohacter pylori eradication and reduced duodenal and gastric ulcer recurrence. Gastroenterol. 110: 1244-1252 (1996) https://doi.org/10.1053/gast.1996.v110.pm8613015
  8. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicohacter pylori infection and the risk of gastric carcinoma. New England J. Med. 325: 1127-1131 (1991) https://doi.org/10.1056/NEJM199110173251603
  9. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD. Helicobacter pylori infection and gastric lymphoma. New England J. Med. 330: 1267-1271 (1994) https://doi.org/10.1056/NEJM199405053301803
  10. Park, MJ, Kim JS, Yim JY, The effect of a fermented milk containing Lactobacilli on Helicobacter pylori in human gastric mocosa. Korean J. Gastroenterol. 38: 233-240 (2001)
  11. Brenner H, Rothenbacher D, Bode G, Adler G. Inverse graded relation between alcohol consumption and active infection with Helicobacter pylori. Am. J. Epidemiol. 149: 571-576 (1999) https://doi.org/10.1093/oxfordjournals.aje.a009854
  12. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J. Natl. Cancer Inst. 92: 1881-1888 (2000) https://doi.org/10.1093/jnci/92.23.1881
  13. Mabe K, Yamada M, Oguni I, Takahashi T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob. Agents Chemother.43: 1788-1791 (1999)
  14. Patterson R, Youngner JS, Weigle WO, Dixon FJ. Antibody production and transfer to egg yolk in chickens. J. Immunol. 89: 272-278 (1962)
  15. Otake S, Nishihara Y, Makimura M, Hatta H, Kim M, Yamamoto T, Hirasawa M. Protection of rats against dental caries by passive immunization with hen-egg-yolk antibody (lgY). J. Dent. Res. 70: 162-166 (1991) https://doi.org/10.1177/00220345910700030101
  16. Ma JK, Hunjan M, Smith R, Lehner T. Specificity of monoclonal antibodies in local passive immunization against Streptococcus mutans. Clin. Exp. Immunol. 77: 331-337 (1989)
  17. Atlas, RM. Urea broth base. p. 968. In Parks LC (ed). Handbook of microbiological media. CRC press
  18. Sogn GA, Kim YJ, Kim TO, Kim HW, Park SK, Kang DH, Song CS, Cho M, Yang US. An associatioin of cagA+ helicobacter pylori infection with cell proliferation in gastric mucosae of gastritis and gastric cancerpatients. Korean J. Gastroenterol. 57: 158-167 (1999)
  19. Voller A, Bartlett A, Bidwell DE. Enzyme immunoassays with special reference to ELISA techniques. J. Clin. Pathol. 31: 507-20 (1978) https://doi.org/10.1136/jcp.31.6.507
  20. Chang Y, S Min, K Kim, Y Han, J Lee. Delta C-urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia. J. Gastroenterol. Hepatol. 18: 726-732 (2003) https://doi.org/10.1046/j.1440-1746.2003.03049.x
  21. Westblom TU, BD Bhatt. Diagnosis of Helicobacter pylori infection. Curr. Top. Microbiol. Immunol. 241: 215-235 (1999)
  22. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, Bang WG and Roe IH. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin. Diagn. Lab. Immunol. 9: 1061-1066 (2002)
  23. Roe IH, Nam SW, Yang SR, Myung NH, Kim JT, Shin JH. The Promising Effect of Egg Yolk Antibody (Immunoglobulin Yolk) on the Treatment of Helicobacter pylori-associated Gastric Diseases. Korean J. Gastroenterol. 39: 260-269 (2002)
  24. Valle J, Kekki M, Sipponen P, Ihamaki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand. J. Gastroenterol. 31: 545-550 (1996)
  25. Kim YB, Hahm KB, Lee KM, Han SU, Kim MW. Animal Models of Helicobacter pyori Infections. Korean J. Gastroenterol. 37: 399-405 (2001)
  26. Richard L, ferrero. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori infection. Infect. Immunity 66: 1349-1355 (1998)